Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years
- PMID: 65452
- DOI: 10.1007/BF00316148
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years
Abstract
140 MS patients were treated with intensive I.V. cyclophosphamide immunotherapy and 110 were followed over 2-4 years. Annual relapse rate incidence was calculated over a period of 2 years before and after treatment and repeated neurological scores were made during this period. The conclusions are that 62% of the patients were stabilized during 2-4 years and that clinical improvement of the neurological signs was observed in most of the cases. It is concluded that intensive immunosuppression is able to interfere with the pathological processes involved in the pathogenesis of disseminated sclerosis.
Similar articles
-
Cyclophosphamide in relapsing remitting multiple sclerosis.Ital J Neurol Sci. 1990 Jun;11(3):271-4. doi: 10.1007/BF02333857. Ital J Neurol Sci. 1990. PMID: 2387697
-
Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis.J Neurol. 1980;223(3):177-90. doi: 10.1007/BF00313182. J Neurol. 1980. PMID: 6157011
-
Experience with cyclophosphamide in multiple sclerosis: the cons.Neurology. 1988 Jul;38(7 Suppl 2):14-8. Neurology. 1988. PMID: 3290708 Clinical Trial.
-
[Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years].Rev Neurol (Paris). 1989;145(5):369-77. Rev Neurol (Paris). 1989. PMID: 2662340 Review. French.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
Cited by
-
Cyclophosphamide in relapsing remitting multiple sclerosis.Ital J Neurol Sci. 1990 Jun;11(3):271-4. doi: 10.1007/BF02333857. Ital J Neurol Sci. 1990. PMID: 2387697
-
Cyclophosphamide for multiple sclerosis.Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002819. doi: 10.1002/14651858.CD002819.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253481 Free PMC article.
-
T-lymphocyte subpopulations in multiple sclerosis--do they help to judge immunosuppressive therapy?Eur Arch Psychiatry Neurol Sci. 1988;238(2):94-6. doi: 10.1007/BF00452783. Eur Arch Psychiatry Neurol Sci. 1988. PMID: 2850189
-
Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities.Front Neurol. 2021 May 17;12:676095. doi: 10.3389/fneur.2021.676095. eCollection 2021. Front Neurol. 2021. PMID: 34079516 Free PMC article. Review.
-
The need for a new strategy for the treatment of multiple sclerosis.J Neurol. 1988 Jul;235(6):327-9. doi: 10.1007/BF00314226. J Neurol. 1988. PMID: 3171613 No abstract available.